Contact Us Site Map Directions Join our Mailing List
Washington Technology Center Funding & Services Microfabrication Lab Industries Initiative News Forum
News Forum

IsoRay receives approval to market cancer therapy in Canada

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced that Health Canada’s Therapeutic Products Directorate has approved IsoRay's Proxcelan Cs-131 brachytherapy seeds for sale throughout Canada.

In a press release, IsoRay CEO Dwight Babcock stated, “This completes another step in being able to expand the potential distribution of cesium-131 brachytherapy seeds. We initially plan to leverage the relationships of our exclusive U.S. distributor, BrachySciences, and contacts we have made with Canadian physicians who are interested in using cesium-131 to treat their patients. Through these channels we hope to begin to penetrate the Canadian brachytherapy market.”

Related external links (will open a new window):

  • Read the IsoRay press release

    Related WTC links:

  • IsoRay is a WTC client
  • IsoRay signs distribution agreement for prostate brachytherapy product

    - end of post -

    Labels: , ,

  • >> Start a discussion on this topic


    Post a Comment

    Your comments are encouraged. By posting a comment, you grant WTC the right to use the content for promotional or marketing purposes. We review comments during business hours before posting to our site.

    << Back to News Forum Home